The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...

AI and the pharmaceutical market are an ideal match ... Two primary hazards, that can both discount the benefits of using AI as well as derail authentic innovation, are model bias and automation ...

With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.

Additional benefits to leveraging AI include: Generative AI is revolutionising content automation for all industries, but has the potential to significantly disrupt the way pharma companies have ...

Integrating AI tools into drug discovery introduces a mix of opportunities and challenges for startups and large pharmaceutical companies.

There are numerous tangible examples of AI-powered tools providing measurable benefits. At the same ... [+] time, a glimpse into the near future shows that even greater innovations are on the horizon.

Survey finds AI to enhance productivity and cut costs in the next 12 months AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, ...

Laura Florence, chief creative officer of Rise & Run, an IPG Health Company. “In 2025, AI will impact content production in pharma marketing, shifting from cautious experimentation to integrated ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

A global AI in pharma and biotech industry valuation of US$ 1.8 billion was estimated for 2023. The market will reach US$ 13.1 billion by 2034, with a CAGR of 18.8% between 2024 and 2034. Healthcare ...

Generative artificial intelligence (AI) in the pharmaceutical market size is expected to see exponential growth in the next few years. It will grow to $5.47 billion in 2028 with (CAGR) of 31.1% ...